Mineralys Therapeutics, Inc. (MLYS) 10-Year Financial Performance & Capital Metrics

MLYS • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutMineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Show more

Revenue $0
EBITDA -$192M -127.2%
Net Income -$178M -147.3%
EPS (Diluted) -3.66 -83.9%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -82.24% -8.0%
ROIC -107.28% +56.2%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 34.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM9.79%

ROCE

10Y Avg-426.86%

5Y Avg-426.86%

3Y Avg-64.57%

Latest-88.99%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	2.94M	18.73M	31.48M	84.66M	192.4M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	532K	2.42M	5.23M	14.3M	23.82M
SG&A % of Revenue	-	-	-	-	-
Research & Development	2.41M	16.31M	26.25M	70.36M	168.58M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-2.94M	-18.73M	-31.48M	-84.66M	-192.4M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-5.36%	-0.68%	-1.69%	-1.27%
EBITDA+	-3.31M	-19.38M	-31.48M	-84.66M	-192.36M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-4.85%	-0.62%	-1.69%	-1.27%
D&A (Non-Cash Add-back)	0	0	0	0	43K
EBIT	-3.31M	-19.38M	-31.48M	-84.66M	-192.4M
Net Interest Income+	-115K	-27K	0	12.76M	14.59M
Interest Income	0	0	1.68M	12.76M	14.59M
Interest Expense	115K	27K	1.68M	0	0
Other Income/Expense	-483K	-683K	1.68M	12.76M	14.59M
Pretax Income+	-3.43M	-19.41M	-29.8M	-71.9M	-177.81M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-3.43M	-19.41M	-29.8M	-71.9M	-177.81M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-4.66%	-0.54%	-1.41%	-1.47%
Net Income (Continuing)	-3.43M	-19.41M	-29.8M	-71.9M	-177.81M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.74	-3.89	-5.77	-1.99	-3.66
EPS Growth %	-	-4.26%	-0.48%	0.66%	-0.84%
EPS (Basic)	-0.74	-3.89	-5.77	-1.99	-3.66
Diluted Shares Outstanding	4.63M	4.98M	5.17M	36.19M	48.54M
Basic Shares Outstanding	4.63M	4.98M	5.17M	36.19M	48.54M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.47M	11.12M	112.81M	249.1M	205.35M
Cash & Short-Term Investments	1.41M	10.61M	110.11M	236.57M	198.19M
Cash Only	1.41M	10.61M	87.7M	49.3M	114.09M
Short-Term Investments	0	0	22.41M	187.26M	84.1M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	2.7M	12.54M	7.16M
Total Non-Current Assets+	20K	3K	1.63M	2.53M	552K
Property, Plant & Equipment	0	0	0	0	53K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	2.48M	0
Other Non-Current Assets	20K	3K	1.63M	51K	499K
Total Assets+	1.49M	11.13M	114.44M	251.64M	205.9M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	6.49%	9.29%	1.2%	-0.18%
Total Current Liabilities+	5.08M	5.05M	8.07M	10.48M	14.65M
Accounts Payable	529K	763K	1.91M	601K	479K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	4.5M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	313K	665K	1.6M	0
Current Ratio	0.29x	2.20x	13.98x	23.76x	14.02x
Quick Ratio	0.29x	2.20x	13.98x	23.76x	14.02x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	29M	158.64M	0	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	29M	158.64M	0	0
Total Liabilities	5.08M	34.05M	166.71M	10.48M	14.65M
Total Debt+	4.5M	0	0	0	0
Net Debt	3.09M	-10.61M	-87.7M	-49.3M	-114.09M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-25.59x	-693.52x	-18.78x	-	-
Total Equity+	-3.6M	-22.93M	-52.27M	241.15M	191.26M
Equity Growth %	-	-5.37%	-1.28%	5.61%	-0.21%
Book Value per Share	-0.78	-4.60	-10.12	6.66	3.94
Total Shareholders' Equity	-3.6M	-22.93M	-52.27M	241.15M	191.26M
Common Stock	1K	1K	1K	4K	5K
Retained Earnings	-3.6M	-23.01M	-52.81M	-124.71M	-302.52M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	-251.64M	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.46M	-14.56M	-29.22M	-81.17M	-166.31M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-4.91%	-1.01%	-1.78%	-1.05%
Net Income	-3.43M	-19.41M	-29.8M	-71.9M	-177.81M
Depreciation & Amortization	0	0	0	0	43K
Stock-Based Compensation	0	80K	455K	5.06M	11.34M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	483K	684K	-649K	-6.87M	-9.4M
Working Capital Changes	480K	4.08M	772K	-7.47M	9.52M
Change in Receivables	0	0	0	-355K	424K
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	0	0
Cash from Investing+	0	0	-21.76M	-160.47M	114.96M
Capital Expenditures	0	0	0	0	-96K
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	3.83M	23.81M	128.02M	203.25M	116.14M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	0	0	258K	83K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-2.46M	-14.56M	-29.22M	-81.17M	-166.41M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-4.91%	-1.01%	-1.78%	-1.05%
FCF per Share	-0.53	-2.92	-5.65	-2.24	-3.43
FCF Conversion (FCF/Net Income)	0.72x	0.75x	0.98x	1.13x	0.94x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-76.13%	-82.24%
Return on Invested Capital (ROIC)	-	-	-	-244.77%	-107.28%
Interest Coverage	-25.59x	-693.52x	-18.78x	-	-
FCF Conversion	0.72x	0.75x	0.98x	1.13x	0.94x

Frequently Asked Questions

Growth & Financials

Mineralys Therapeutics, Inc. (MLYS) grew revenue by 0.0% over the past year. Growth has been modest.

Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $171.4M for fiscal year 2024.

Dividend & Returns

Mineralys Therapeutics, Inc. (MLYS) has a return on equity (ROE) of -82.2%. Negative ROE indicates the company is unprofitable.

Mineralys Therapeutics, Inc. (MLYS) had negative free cash flow of $171.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener